Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Dec;22(6):721–724. doi: 10.1111/j.1365-2125.1986.tb02964.x

Pharmacokinetic profile of indoprofen in elderly subjects.

B Lund, C Egsmose, O Knudsen, R B Andersen
PMCID: PMC1401207  PMID: 3567017

Abstract

Multiple dosing four times daily for 7 days of indoprofen 200 mg, a non-steroidal anti-inflammatory drug with a short half-life (t1/2), revealed drug accumulation in eight elderly subjects. This indicates a substantially longer t1/2 (11 h) than that reported in young persons (3 h). A reduction in dose compared to younger subjects is recommended in elderly patients with osteoarthritis.

Full text

PDF
721

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alván G., Orme M., Bertilsson L., Ekstrand R., Palmér L. Pharmacokinetics of indomethacin. Clin Pharmacol Ther. 1975 Sep;18(3):364–373. doi: 10.1002/cpt1975183364. [DOI] [PubMed] [Google Scholar]
  2. Baber N., Halliday L. D., van den Heuvel W. J., Walker R. W., Sibeon R., Keenan J. P., Littler T., Orme M. L. Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and nonresponders. Ann Rheum Dis. 1979 Apr;38(2):128–136. doi: 10.1136/ard.38.2.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bjornsson T. D., Shand D. G. Estimation of kinetic parameters from a two-point determination of the drug cumulation factor. Clin Pharmacol Ther. 1979 Nov;26(5):540–547. doi: 10.1002/cpt1979265540. [DOI] [PubMed] [Google Scholar]
  4. Caruso I., Corvi G., Fuccella L. M., Moro E., Sacchetti G., Tamassia V., Tosolini G. P. Pharmacokinetic studies of indoprofen in healthy volunteers and in patients. Int J Clin Pharmacol Biopharm. 1977 Sep;15(9):411–416. [PubMed] [Google Scholar]
  5. Caruso I., Moro E., Patrono C., Sacchetti G., Tamassia V., Tosolini G. P. Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. Scand J Rheumatol. 1980;9(2):123–126. doi: 10.3109/03009748009098141. [DOI] [PubMed] [Google Scholar]
  6. Faed E. M. Decreased clearance of diflunisal in renal insufficiency--an alternative explanation. Br J Clin Pharmacol. 1980 Aug;10(2):185–186. doi: 10.1111/j.1365-2125.1980.tb01744.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hamdy R. C., Murnane B., Perera N., Woodcock K., Koch I. M. The pharmacokinetics of benoxaprofen in elderly subjects. Eur J Rheumatol Inflamm. 1982;5(2):69–75. [PubMed] [Google Scholar]
  8. Hobbs D. C., Twomey T. M. Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. J Clin Pharmacol. 1979 May-Jun;19(5-6):270–281. doi: 10.1002/j.1552-4604.1979.tb02480.x. [DOI] [PubMed] [Google Scholar]
  9. Kamal A., Koch I. M. Pharmacokinetic studies of benoxaprofen in geriatric patients. Eur J Rheumatol Inflamm. 1982;5(2):76–81. [PubMed] [Google Scholar]
  10. Kampmann J., Siersbaek-Nielsen K., Kristensen M., Hansen J. M. Rapid evaluation of creatinine clearance. Acta Med Scand. 1974 Dec;196(6):517–520. doi: 10.1111/j.0954-6820.1974.tb01053.x. [DOI] [PubMed] [Google Scholar]
  11. Kwan K. C., Breault G. O., Umbenhauer E. R., McMahon F. G., Duggan D. E. Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man. J Pharmacokinet Biopharm. 1976 Jun;4(3):255–280. doi: 10.1007/BF01063617. [DOI] [PubMed] [Google Scholar]
  12. Lanbeck K., Lindström B., Wibell L. High-performance liquid chromatographic determination of indoprofen in plasma and urine. J Chromatogr. 1980 May 9;182(2):262–266. doi: 10.1016/s0378-4347(00)81634-5. [DOI] [PubMed] [Google Scholar]
  13. Levy G. Decreased body clearance of diflunisal in renal insufficiency--an alternative explanation. Br J Clin Pharmacol. 1979 Dec;8(6):601–601. doi: 10.1111/j.1365-2125.1979.tb01055.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Meffin P. J., Zilm D. M., Veenendaal J. R. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle. J Pharmacol Exp Ther. 1983 Dec;227(3):732–738. [PubMed] [Google Scholar]
  15. O'Malley K., Crooks J., Duke E., Stevenson I. H. Effect of age and sex on human drug metabolism. Br Med J. 1971 Sep 11;3(5775):607–609. doi: 10.1136/bmj.3.5775.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Ritch A. E., Perera W. N., Jones C. J. Pharmacokinetics of azapropazone in the elderly. Br J Clin Pharmacol. 1982 Jul;14(1):116–119. doi: 10.1111/j.1365-2125.1982.tb04947.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Verbeeck R., Tjandramaga T. B., Mullie A., Verbesselt R., Verberckmoes R., de Schepper P. J. Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency. Br J Clin Pharmacol. 1979 Mar;7(3):273–282. doi: 10.1111/j.1365-2125.1979.tb00932.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wibell L., Nilsson P., Lindström B. Kinetics of indoprofen in patients with renal insufficiency (a preliminary report). Eur J Rheumatol Inflamm. 1981;4(1):16–21. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES